June 3, 2020 / 12:33 PM / a month ago

BRIEF-BeyondSpring Reports Board Recommendation For Plinabulin To Continue NSCLC Study Without Modification

June 3 (Reuters) - Beyondspring Inc:

* BEYONDSPRING ANNOUNCES DATA & SAFETY MONITORING BOARD RECOMMENDATION FOR PLINABULIN TO CONTINUE NSCLC PHASE 3 DUBLIN-3 STUDY WITHOUT MODIFICATION

* BEYONDSPRING INC - DATA CONTINUE TO SUPPORT PLINABULIN’S IMMUNE MECHANISM-TARGETED PATIENT SELECTION

* BEYONDSPRING INC - REACHED SECOND INTERIM ANALYSIS FOR ITS PHASE 3 DUBLIN-3 IN TREATMENT OF NON-SMALL CELL LUNG CANCER WITH PLINABULIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below